ÕâÏîµ¥±Û¡¢»ØÊ×ÐÔ¡¢ÕæʵÌìÏÂÑо¿¹²ÄÉÈëÁË364Àý½ÓÊÜGLP-1RAÖÎÁÆÖÁÉÙ6¸öÔµÄÇáÖжÈDKD»¼Õß£¬£¬£¬£¬£¬ÆäÖаüÀ¨¾ÛÒÒ¶þ´¼ÂåÈûÄÇëÄ£¨ÉÌÆ·Ãû£ºæÚÀ´ÃÀ^?£©159Àý¡¢¶ÈÀ­ÌÇëÄ104Àý¡¢Ë¾ÃÀ¸ñ³ëÄ52Àý¡¢ÀûÀ­Â³ëÄ49Àý¡£¡£¡£¡£¡£¡£Ö÷ÒªÖÕµãÊÇÖÎÁÆ6¸öÔÂʱµÄÌÇ»¯ÑªºìÂÑ°×£¨HbA1c£©Ë®Æ½^[1]¡£¡£¡£¡£¡£¡£

ÖµµÃ×¢ÖصÄÊÇ£¬£¬£¬£¬£¬Ö»¹ÜʹÓþÛÒÒ¶þ´¼ÂåÈûÄÇëÄÖÎÁƵĻ¼ÕßÊýÄ¿×î¶à£¬£¬£¬£¬£¬µ«Æä賦µÀ·´Ó¦µÄ×ܱ¬·¢ÂÊ£¨17.6%vs30.6%~51%£©ºÍµÍѪÌDZ¬·¢ÂÊ£¨3.1%vs8.2%~11.5%£©¾ùµÍÓÚÆäËüGLP-1RA¡£¡£¡£¡£¡£¡£

Ñо¿»¹·¢Ã÷£¬£¬£¬£¬£¬ÎÞÂÛÊÇ·ñʹÓÃѪ¹ÜÖ÷ÒªËØת»»Ã¸ÒÖÖƼÁ/Ѫ¹ÜÖ÷ÒªËØ¢òÊÜÌå×èÖͼÁ£¨ACEi/ARB£©ÀàÉö±£»£»£»£»£»¤Ò©£¬£¬£¬£¬£¬GLP-1RA¾ùÄܽµµÍÂÑ°×Äò£¬£¬£¬£¬£¬ÇÒÔ½ÔçʹÓÃGLP-1RAµÄ»¼Õ߸ÄÉÆÔ½ÏÔ×Å^[1]¡£¡£¡£¡£¡£¡£

DKDÊÇÊÇÌÇÄò²¡µÄÖ÷Òª²¢·¢Ö¢Ö®Ò»^[2]¡£¡£¡£¡£¡£¡£Ô¼ÓÐ30%¨C40%µÄÌÇÄò²¡»¼Õß°éÓÐDKD^[3]£¬£¬£¬£¬£¬Êǵ¼ÖÂÖÕÄ©ÆÚÉö²¡(ESRD)µÄÖ÷ÒªÔµ¹ÊÔ­ÓÉ^[4]¡£¡£¡£¡£¡£¡£

¼ÈÍùÔøÓÐËæ»ú±ÈÕÕÑо¿Ö¤ÊµÁ˾ÛÒÒ¶þ´¼ÂåÈûÄÇëĶÔÇáÖжÈDKD»¼ÕßµÄÁÆЧÓëÒ»ÏßµÄSGLT2ÒÖÖƼÁ´ï¸ñÁо»Ï൱£¬£¬£¬£¬£¬ÇÒ¾ßÓиÄÉÆÖ¬ÖÊˮƽµÄÌØÊâ»ñÒæ^[5]¡£¡£¡£¡£¡£¡£ÕâÏîÕæʵÌìÏÂÑо¿ÔòÔÙ´Î֤ʵÁ˾ÛÒÒ¶þ´¼ÂåÈûÄÇëÄÄܹ»ÎªÇáÖжÈDKD»¼Õß´øÀ´½µÌÇ¡¢½µÑ¹¡¢¼õÖØ¡¢¸ÄÉÆѪ֬ºÍÑÓ»ºÉöÔàÏ£ÍûµÈ¶àÖØ»ñÒæ£¬£¬£¬£¬£¬ÇÒÔÚÇå¾²ÐÔÉÏÏà±ÈÆäËüGLP-1RA¸ü¾ßÓÅÊÆ£¬£¬£¬£¬£¬Õ⽫ÓÐÖú¸ÄÉÆ»¼ÕßµÄÉúÑÄÖÊÁ¿²¢Ìá¸ßÒÀ´ÓÐÔ¡£¡£¡£¡£¡£¡£¾ÛÒÒ¶þ´¼ÂåÈûÄÇëĵĶàÖØ»ñÒæºÍÇå¾²ÐÔÓÅÊƽ«ÎªDKD»¼Õß´øÀ´¸üÓŵÄÖÎÁÆÑ¡Ôñ¡£¡£¡£¡£¡£¡£

²Î¿¼ÎÄÏ×£º

[1] Ying Liu et al. Real-world clinical effectiveness of glucagon-like peptide-1 receptor agonist on mild-to-moderate diabetic kidney disease in patients with type 2 diabetes: a retrospective, single-arm clinical trial.Diabetes, Metabolic Syndrome and Obesity 2024:17 2913¨C2921. 

[2] Mohandes S, Doke T, Hu H, et al. Molecular pathways that drive diabetic kidney disease. J Clin Invest. 2023;15;133:e165654. 

[3] Bonner R, Albajrami O, Hudspeth J, et al. Diabetic kidney disease. Prim Care. 2020;47:645-659.

[4] Mima A, Nomura A, Fujii T. Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: a narrative review. Biomed Pharmacother. 2023;165:115032.

[5] Cao Y, Cao S, Zhao J, Zhao J, Zhao Y and Liu Y (2024) Efficacy and safety of polyethylene glycol loxenatide in treating mild-to-moderate diabetic kidney disease in type 2 diabetes patients: a randomized, open-label, clinical trial.Front. Endocrinol. 15:1387993.